Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 June 2024 | Story Martinette Brits | Photo Supplied
Arran Wood pictured with Prof Jan Smith
Arran Wood pictured with Prof Jan Smith, Senior Lecturer at the Department of Architecture, in front of his project.

A former Master’s student in Architecture at the University of the Free State (UFS) has recently been honoured with the esteemed Corobrik National Student Architecture Award. The 2023 grand prize was awarded to Arran Wood from UFS for his project "Spectral Flesh – Remembrance," which explores South Africa's forgotten nuclear history.

Corobrik’s vision for this competition is to provide up-and-coming architecture students a platform to showcase their architectural talent and creativity. The eight finalists were chosen by major South African universities, each selecting its best Master’s architectural student to participate in the awards.

The eight regional finalists had the opportunity to present their theses to an esteemed panel of judges, including Carin Smuts from CS Studio Architects, Somers Govender from Artek 4 Architects and Rudolf Roos from HDG Pretoria.

Unveiling forgotten conflict: Architecture as a mediator and reminder

Wood’s project delves into the role architecture can play as a mediator and reminder of forgotten conflicts. “The Angola-South African War left extensive scars and remains a raw place in the lives of many South Africans. Yet the memory and memorialisation of the conflict have become a shrouded spectre. One of the most obscured fallouts of the war was the fact that South Africa managed to construct nuclear weapons and became the first nation to decommission their nuclear arsenal voluntarily,” Wood explained.

The thesis proposes a theoretical foundry and “inverted monument” at the forgotten nuclear weapons development site at Pelindaba near Hartbeesport Dam. He chose this project due to his interest in the relationship between architecture and memory, particularly the memory of warfare. “I wanted to focus my research on something specific to South Africa. I settled on the Angola-South African War because its fallout is still a relevant struggle that many people deal with, yet it remains largely unspoken. This led me to discover how intimately the nuclear weapons programme was connected to the conflict,” Wood stated. 

Awards pave the way to success

Wood mentioned that he had known about the prestigious Corobrik Awards early in his studies but only realised later that one winner is chosen to represent the whole country. “Winning the national award still feels a bit unreal. From prior experience, I have seen how the award's prestige follows the winners long into their careers, standing as a significant achievement. It is a great honour to be considered one of these winners, and I am very grateful for the lasting recognition the award brings to my career.”

He credited the lecturers and staff at the Department of Architecture for their significant role in his success. “They taught me what I know, and it was most inspiring to see their passion for architecture. The support from the lecturers at this incredible department goes far beyond their job descriptions,” he remarked.

Wood also won the Dean’s Medal for the best results in the final-year Master’s class during the April graduation ceremonies of UFS. He is currently working for an architectural firm in Cape Town, named TwoFiveFive Architects

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept